SOUTHWEST ONCOLOGY GROUP - OPERATIONS OFFICE

描述(由申请人提供)：西南肿瘤学小组是一个成人，多疾病，多模式临床癌症研究组织，拥有35个成员机构，29个社区临床肿瘤计划(CCOP)机构，包括7个以少数族裔为基础的CCOP，27个泌尿系癌症外展计划(UCOP)成员，以及189个办事处和医院的1036名附属计划调查员网络，以及12个参与CTEP少数族裔计划的机构。 该小组的一个特别重点是由1992年设立的更名为特殊人口委员会管理。该委员会的研究和教育议程已扩大到包括：女性(或男性)、老年癌症患者、癌症幸存者和种族/少数民族群体(非洲裔美国人、西班牙裔美国人和亚裔美国太平洋岛民)。让患者权益倡导者参与小组活动是该委员会的一个重要角色。委员会的报告详细介绍了跨委员会的研究和出版物。 通过伦理培训、利益冲突政策、对完整性和数据的肯定以及安全监测，强调小组成员在临床研究中的道德和伦理行为。 除了介绍与疾病委员会相关的肿瘤库相关的科学活动外，我们还建议成立一个相关科学委员会，该委员会将在集团的六个疾病委员会相关科学项目中提供科学监督和检测技术的质量保证。 这个应用程序中有三个新的计划。两项新的成人医学肿瘤学小组提案，一个涉及晚期妇科癌症，美国妇科小组，第二个涉及肉瘤，美国/加拿大肉瘤小组。第三个是早期治疗委员会，它将利用集团中持有NCI资助的U-01第一阶段的10个机构。通过我们统计中心实施的新的基于网络的多用户第一阶段监测系统，这将是可能的。

DESCRIPTION (provided by applicant): The Southwest Oncology Group is an adult, multi-disease, multi-modality clinical cancer research organization with 35 Member Institutions, 29 Community Clinical Oncology Program (CCOP) institutions, including 7 Minority-Based CCOPs, 27 Urologic Cancer Outreach Program (UCOP) members, and a network of 1,036 Affiliate Program investigators at 189 offices and hospitals, and 12 institutions participating in the CTEP Minority program. A special emphasis of the Group is managed by the renamed Committee on Special Populations, established in 1992. The committee's research and education agenda has broadened to include: women (or men), older cancer patients, cancer survivors, and racial/ethnic minority groups (African-American, Hispanic Americans and Asian American Pacific Islanders). Involving patient advocates in Group activities is an important role of this committee. The committee report details the cross-committee research and publications. The moral and ethical conduct of clinical research by the group members is emphasized by ethics training, the conflict of interest policy, affirmation of integrity and data and safety monitoring. In addition to the presentation of correlative sciences activities tied to tumor banks related to disease committees, we propose a Correlative Sciences Committee, which will provide oversight of science and quality assurance of assay technology across the six disease committee correlative science programs in the Group. There are three new initiatives in this application. Two new adult medical oncology Intergroup proposals, one dealing with advanced gynecologic cancer, the U.S. Gynecology Intergroup, and the second dealing with sarcomas, The U.S./Canada Sarcoma Intergroup. The third is the Early Therapeutics Committee, which will take advantage of the 10 institutions in the Group who hold Phase I NCI funded U-01s. This will be possible with the new Web-Based, Multi-User Phase I Monitoring System implemented by our Statistical Center.